CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

CiclesonideWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug3053 ıt will be compared pain, sleep, fatigue, physical activity level and quality of life and questioning exercise habits before and after the covid-19 outbreak in patients with Behçet and FMF. Wiki 0.71
drug1879 Positive Peer Journaling (PPJ) Wiki 0.71
drug1822 Placebo Wiki 0.04

Correlated MeSH Terms (5)

Name (Synonyms) Correlation
D056660 Hereditary Autoinflammatory Diseases NIH 0.71
D001528 Behcet Syndrome NIH 0.71
D010505 Familial Mediterranean Fever NIH 0.71
D002006 Brucellosis NIH 0.71
D016739 Behavior, Addictive NIH 0.35

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0030858 Addictive behavior HPO 0.35

There are 2 clinical trials

Clinical Trials

1 A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Ciclesonide Metered-Dose Inhaler in Non-hospitalized Patients 12 Years of Age and Older With Symptomatic COVID-19 Infection

The purpose of this study is to assess the safety and efficacy of Alvesco (ciclesonide) Inhalation Aerosol in non hospitalized patients with symptomatic COVID-19 infection in a multicenter, randomized, double-blind, placebo controlled study

NCT04377711 COVID-19 Drug: Ciclesonide Drug: Placebo

Primary Outcomes

Measure: Percentage of patients hospital admission or death by day 30

Time: Day 30

Secondary Outcomes

Measure: All-cause mortality by day 30

Time: Day 30

Measure: COVID-19-related mortality by day 30

Time: Day 30

Measure: Percentage of patients with subsequent emergency department visit or hospital admission for reasons attributable to COVID 19 by day 30

Time: Day 30

Measure: Time to hospital admission or death

Time: Day 30

Measure: Time to alleviation of COVID-19-related symptoms of cough, dyspnea, chills, and feeling feverish, defined as symptom-free for a continuous period of more than 24 hours (ie, > 3 AM/PM assessments)

Time: Day 30

Measure: Change from baseline in oxygen saturation levels

Time: Day 30

Measure: Change from baseline in COVID-19 viral load in nasopharyngel sample nasal secretions at day 30

Time: Day 30

Measure: Safety will be assessed based on adverse events.

Time: Day 60

2 Ciclesonide Clinical Trial for COVID-19 Treatment

The CONTAIN (CiclesOnide cliNical TriAl covId-19 treatmeNt) is a randomized control study of ciclesonide vs placebo for mild covid-19 disease. The need for potential therapy for COVID-19 patients is urgent. Ciclesonide has shown encouraging in vitro results, is easy to be used and is readily available. It has a low rate of side effects and few interactions with other drugs. It is unusual to use an inhaled steroid drug for COVID-19 but there has been new data suggesting steroids may have an antiviral effect in addition to an anti-inflammatory effect. We propose to use inhaled and nasal ciclesonide to stop viral replication in the nose and airways. We hope this will accelerate recovery from COVID-19 illness in individuals who are not admitted to hospital at time of diagnosis of COVID-19.

NCT04435795 COVID 19 Drug: Ciclesonide

Primary Outcomes

Description: Dyspnea improvement is defined as a 15%, or greater, decline in dyspnea intensity. To measure dyspnea intensity, we will use a validated patient reported outcome measure called the Promis dyspnea characteristics scale.

Measure: Improvement in dyspnea at day 7

Time: day 7

Secondary Outcomes

Description: Hospitalization for SARS-CoV-2 related illness at day 14

Measure: Hospitalization at day 14

Time: day 14

Description: Incidence and duration of new oxygen use during the trial (defined as oxygen use not present at randomization) at day 14

Measure: Oxygen Use

Time: day 14

Description: All cause mortality

Measure: Mortality

Time: day 14 and 29

Description: Ordinal Scale for Evaluating subject Clinical Status at day 7 and 14

Measure: Clinical status

Time: day 7 and 14

Description: Promis Anxiety 7a scale

Measure: Anxiety

Time: day 7 and 14

Description: Promis Sleep disturbance 4a scale

Measure: Sleep Disturbance

Time: day 7 and 14

Description: The "Three-minute step test" will be measured in men and women to determine the impact of SARS-CoV-2 on exercise capacity

Measure: Exercise capacity

Time: day 7 and 14

No related HPO nodes (Using clinical trials)